1 |
Tildrakizumab |
Tildrakizumab |
[1] D10400 D10400 💬 |
IL23A [1] IL23A 💬 |
C-type lectin receptor signaling pathway [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
162 [2] 162, 271 💬 |
2 |
Tildrakizumab 100 mg (one 1-ml injection of 100 mg/ml |
Tildrakizumab |
[1] D10400 D10400 💬 |
IL23A [1] IL23A 💬 |
C-type lectin receptor signaling pathway [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
271 [1] 271 💬 |
3 |
Tildrakizumab 100 mg/ml |
Tildrakizumab |
[1] D10400 D10400 💬 |
IL23A [1] IL23A 💬 |
C-type lectin receptor signaling pathway [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
271 [1] 271 💬 |
4 |
Tildrakizumab 200 mg (two 1-ml injections of 100 mg/ml) |
Tildrakizumab |
[1] D10400 D10400 💬 |
IL23A [1] IL23A 💬 |
C-type lectin receptor signaling pathway [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
271 [1] 271 💬 |
5 |
Tildrakizumab prefilled syringe |
Tildrakizumab |
[1] D10400 D10400 💬 |
IL23A [1] IL23A 💬 |
C-type lectin receptor signaling pathway [9] C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis |
162 [1] 162 💬 |